[Congressional Record Volume 167, Number 213 (Thursday, December 9, 2021)]
[Senate]
[Page S9093]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                         REPORTS OF COMMITTEES

  The following reports of committees were submitted:

       By Mr. DURBIN, from the Committee on the Judiciary, with an 
     amendment in the nature of a substitute:
       S. 1428. A bill to prohibit brand name drug companies from 
     compensating generic drug companies to delay the entry of a 
     generic drug into the market, and to prohibit biological 
     product manufacturers from compensating biosimilar and 
     interchangeable companies to delay the entry of biosimilar 
     biological products and interchangeable biological products.

                          ____________________